Companies · Software / Tech
LOS ANGELES · Software / Tech · refined from filed group “Other Health Care”
Diligence memoA one-page analyst read on BioSig Technologies, Inc. — recommendation, valuation, rhythm, risks.→BioSig Technologies, Inc. has raised $66M over 39 rounds; too few niche peers to rank its valuation yet.
Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the technology sector profile.
Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.
Procedural diagnosis est. — rule-based common-sense checks over the filing pattern, issuer name, activity cadence, and surfaced operating evidence.
BioSig Technologies, Inc. behaves more like a recurring private-offering issuer than a conventional venture-backed operating company.
No named principal in this company's public records yet — see all operators below.
Explore how these operators interlock with other companies in the operator network.
BioSig Technologies, Inc. is one of 3920 Software / Tech companies tracked from LOS ANGELES. By capital raised it ranks among the largest (ahead of 93% of sector peers), and in the long tail by modeled valuation est..
Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.
As reported in public records reported — not modeled.
This issuer has a dense recurring filing history, so the chart groups filings by year. Solid bars are annual reported capital reported; hatched bars show the latest modeled value est. observed in that year. Use the toggles to overlay data labels and the niche-peer / market average value lines.
Dense history compressed: 52 filings shown as 14 yearly buckets. Hover a bucket for filing count, annual capital, and latest modeled value.
The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.
This looks like a recurring offering series, so a VC stage ladder would be misleading. Showing the filed offering sequence instead.
Showing first 24 of 52 filings to keep the sequence readable.
This issuer files recurring offerings, so the model treats stage labels as a loose sizing heuristic, not a clean VC ladder. The estimate anchors on reported filing amounts and dates, then applies benchmark dilution, survival, and markup assumptions. Directional, not a quoted figure.
Benchmarked against 3920 companies in Software / Tech. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.
Raised more than 93% of sector peers (real $). Modeled value above 12% of peers (estimate).
This issuer files too frequently for VC stage labels to be meaningful, so rows are shown as initial/follow-on offerings est. instead of Pre-Seed/Seed/Series buckets.
| Stage | Amount · real | Announced | Post-money · est | Value · est | Conf. |
|---|---|---|---|---|---|
| Initial offering | $922K | 2011-09-19 | $5.1M | $39.1M | 85% |
| Follow-on offering | $922K | 2011-09-19 | $5.1M | $39.1M | 85% |
| Follow-on offering | $888K | 2011-12-27 | $4.9M | $37.6M | 85% |
| Follow-on offering | $2.2M | 2013-02-12 | $11.2M | $76.2M | 85% |
| Follow-on offering | $2.4M | 2013-02-12 | $12.1M | $82.5M | 85% |
| Follow-on offering | $1.8M | 2013-02-12 | $9.1M | $62.0M | 85% |
| Follow-on offering | $2.8M | 2013-02-12 | $13.9M | $94.8M | 85% |
| Follow-on offering | $792K | 2013-12-31 | $4.0M | $27.0M | 85% |
| Follow-on offering | $528K | 2013-12-31 | $2.9M | $22.4M | 85% |
| Follow-on offering | $574K | 2014-04-04 | $2.9M | $19.6M | 85% |
| Follow-on offering | $205K | 2014-04-04 | $1.1M | $8.7M | 85% |
| Follow-on offering | $563K | 2014-08-15 | $3.1M | $23.9M | 85% |
| Follow-on offering | $953K | 2014-08-15 | $4.8M | $32.5M | 85% |
| Follow-on offering | $1.6M | 2014-12-19 | $7.9M | $53.9M | 85% |
| Follow-on offering | $2.4M | 2014-12-19 | $12.1M | $82.6M | 85% |
| Follow-on offering | $512K | 2014-12-19 | $2.8M | $21.7M | 85% |
| Follow-on offering | $3.0M | 2014-12-19 | $14.9M | $101.6M | 85% |
| Follow-on offering | $4.0M | 2014-12-19 | $18.2M | $111.2M | 85% |
| Follow-on offering | $450K | 2015-05-11 | $2.0M | $12.5M | 85% |
| Follow-on offering | $1.0M | 2015-10-23 | $4.6M | $28.3M | 85% |
| Follow-on offering | $520K | 2016-10-28 | $2.4M | $14.4M | 90% |
| Follow-on offering | $1.6M | 2017-04-06 | $7.5M | $45.5M | 90% |
| Follow-on offering | $2.0M | 2017-11-03 | $9.1M | $55.5M | 90% |
| Follow-on offering | $1.5M | 2018-02-16 | $6.8M | $41.6M | 90% |
| Follow-on offering | $4.1M | 2018-08-13 | $18.5M | $112.9M | 90% |
| Follow-on offering | $8.6M | 2019-03-14 | $39.2M | $239.1M | 90% |
| Follow-on offering | $3.3M | 2019-08-05 | $14.8M | $90.4M | 90% |
| Follow-on offering | $160K | 2019-09-05 | $727K | $4.4M | 90% |
| Follow-on offering | $686K | 2019-10-21 | $3.1M | $19.0M | 90% |
| Follow-on offering | $600K | 2020-02-25 | $2.7M | $16.6M | 90% |
| Follow-on offering | $600K | 2021-07-07 | $2.7M | $11.0M | 90% |
| Follow-on offering | $1.5M | 2022-11-18 | $6.6M | $15.4M | 90% |
| Follow-on offering | $1.5M | 2022-11-18 | $7.3M | $15.9M | 90% |
| Follow-on offering | $1.1M | 2022-12-21 | $5.0M | $11.2M | 90% |
| Follow-on offering | $1.8M | 2023-01-10 | $9.1M | $18.6M | 90% |
| Follow-on offering | $1.8M | 2023-01-10 | $8.2M | $18.1M | 90% |
| Follow-on offering | $1.9M | 2023-01-23 | $8.6M | $18.7M | 90% |
| Follow-on offering | $234K | 2023-01-25 | $1.1M | $2.3M | 90% |
| Follow-on offering | $2.0M | 2023-02-03 | $9.1M | $19.4M | 90% |
| Follow-on offering | $603K | 2023-02-08 | $2.7M | $5.8M | 90% |
| Follow-on offering | $2.5M | 2023-03-14 | $11.5M | $23.6M | 90% |
| Follow-on offering | $1.5M | 2023-03-24 | $6.8M | $13.8M | 90% |
| Follow-on offering | $1.4M | 2023-04-18 | $6.3M | $12.5M | 90% |
| Follow-on offering | $3.7M | 2023-05-16 | $16.8M | $32.1M | 90% |
| Follow-on offering | $2.2M | 2023-07-31 | $10.0M | $17.6M | 90% |
| Follow-on offering | $794K | 2023-09-12 | $3.6M | $6.0M | 90% |
| Follow-on offering | $1.2M | 2023-09-21 | $5.3M | $8.8M | 90% |
| Follow-on offering | $861K | 2023-10-12 | $3.9M | $6.3M | 90% |
| Follow-on offering | $1.5M | 2024-01-12 | $6.7M | $9.8M | 90% |
| Follow-on offering | $1.1M | 2024-05-01 | $5.2M | $6.7M | 90% |
| Follow-on offering | $3.0M | 2024-05-29 | $13.6M | $17.1M | 90% |
| Follow-on offering | $819K | 2025-03-05 | $3.7M | $3.4M | 90% |
Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.
Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.
Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.
| Person | Role | Also runs | Tied since |
|---|---|---|---|
| Patrick Gallagher | — | 10 other | 2014-08 |
| Jeffrey O'Donnell | — | 6 other | 2013-12 |
| Jerome Zeldis | — | 5 other | 2015-05 |
| Roy Tanaka | — | 5 other | 2013-12 |
| Kenneth Londoner | — | 4 other | 2011-09 |
| Anthony Zook | — | 3 other | 2021-07 |
| Asher Holzer | — | 3 other | 2013-12 |
| Patrick J. Gallagher | — | 3 other | 2022-11 |
| Samuel Navarro | — | 3 other | 2019-08 |
| Kalyanam Shivkumar | — | 2 other | 2013-12 |
| David Weild | — | 1 other | 2015-10 |
| Gregory Cash | — | 1 other | 2014-08 |
| James J. Barry | — | 1 other | 2022-11 |
| Steve Chaussy | — | 1 other | 2013-12 |
| Andrew Filler | — | — | 2017-11 |
| Anthony Amato | — | — | 2024-05 |
| Asher S Holzer | — | — | 2013-02 |
| Bill S Uglow | — | — | 2011-09 |
| Budimir S Drakulic | — | — | 2011-09 |
| Chris F. Baer | — | — | 2024-05 |
| David Foley | — | — | 2015-10 |
| David J Weild IV | — | — | 2023-02 |
| David L. Weild IV | — | — | 2022-11 |
| Donald E. Foley | — | — | 2022-11 |
BioSig Technologies, Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.
Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.
| Company | Sector | Stage | Raised · real | Value · est | Why similar |
|---|---|---|---|---|---|
| NeuroClear Technologies, Inc. | Software / Tech | Series A | $14.9M | $298.2M | network6 shared operators · same sector · same stage |
| Alliqua BioMedical, Inc. | Biotechnology | Series A | $52.6M | $100.1M | network2 shared operators · same stage |
| Peca Labs, Inc. | Software / Tech | Series A | $21.2M | $8.4M | network1 shared operator · same sector · same stage |
| Algorithm Sciences, Inc. | Biotechnology | Seed | $7.2M | $1.9M | network3 shared operators |
| NeuTrace, Inc. | Other Health Care | Series A | $9.8M | $23.6M | network2 shared operators · same stage |
| Ovation.io, Inc. | Software / Tech | Series B | $31.0M | $4.9M | network1 shared operator · same sector |
| Phase Change Software Llc | Software / Tech | Series A | $37.4M | $4.7M | same sector · same stage |
| InspireMD, Inc. | Other Health Care | Series C | $117.2M | $248.1M | network2 shared operators |
Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.
| Company | Sector | Stage | Value · est | Match |
|---|---|---|---|---|
| BioSig AI Sciences, Inc. | AI / ML | Seed | $4.5M | 89% |
| DataBiologics, Inc. | Other Health Care | Pre-Seed | $11.2M | 83% |
| BC3 Technologies, Inc. | Software / Tech | Seed | $2.6M | 83% |
| SIG Medical Corp. | Healthtech | Seed | $55.5M | 83% |
| Biosim Inc. | Other Technology | Series A | $79.7M | 82% |
| Pieces Technologies, Inc. | Software / Tech | Series B | $782.9M | 82% |
| Tissue Analytics, Inc. | Software / Tech | Series A | $138.7M | 82% |
| BioMedx Group, Inc. | Other Health Care | Pre-Seed | $14.0M | 82% |
See where BioSig Technologies, Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.
If you work at BioSig Technologies, Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.
Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.